Letter to the Editor: Real-Life Experience of Long-Acting Cabotegravir–Rilpivirine Combination in a Person Living with HIV with Detectable Viremia: A Case Report
Restricted accessLetterFirst published online October, 2024
Letter to the Editor: Real-Life Experience of Long-Acting Cabotegravir–Rilpivirine Combination in a Person Living with HIV with Detectable Viremia: A Case Report
LlibreJM, KuritzkesDR. Long acting cabotegravir and rilpivirine: Innovation, new challenges and opportunities. Clin Infect Dis, 2023; 76(9):1655–1657; doi: 10.1093/cid/ciad024
2.
OvertonET, RichmondG, RizzardiniG, et al.Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection: 152-week results from ATLAS-2M, a randomized, open-label, Phase 3b, noninferiority study. Clin Infect Dis, 2023; 396(10267):1994–2005; doi: 10.1093/cid/ciad020
3.
OrkinC, Bernal MorellE, TanDHS, et al.Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: Week 124 results of the open-label phase 3 FLAIR study. Lancet HIV, 2021; 8(11):e668–e678; doi: 10.1016/S2352-3018(21)00184-3
4.
BarnettSK, Armas-KolostroubisL, SensionM, et al.Cabotegravir-rilpivirine treatment initiation in a nonvirologically suppressed patient. AIDS, 2022; 36(10):1475–1476; doi: 10.1097/QAD.0000000000003273
